New drug cocktail shows promise for follicular lymphoma patients
NCT ID NCT04450173
First seen Apr 21, 2026 · Last updated Apr 28, 2026 · Updated 1 time
Summary
This study tests a combination of three drugs (obinutuzumab, ibrutinib, and venetoclax) in 40 people with untreated follicular lymphoma. The goal is to see if the combination works better than each drug alone at shrinking tumors. Participants receive the drugs and are monitored for side effects and response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GRADE 3A FOLLICULAR LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of California Davis Comprehensive Cancer Center
Sacramento, California, 95817, United States
-
University of California, Los Angeles
Los Angeles, California, 90095, United States
-
University of California, San Diego
San Diego, California, 92037, United States
-
University of California, San Francisco (UCSF) Fresno
Fresno, California, 93701, United States
Conditions
Explore the condition pages connected to this study.